Vertex's Povetacicept BLA Accepted by FDA for Accelerated Approval; PDUFA Nov 30
VRTX sits 23% above its 52-week low of $362.5.
Summary
The FDA has accepted Vertex's Biologics License Application (BLA) for povetacicept, granting it accelerated approval status for IgA Nephropathy. This follows positive Phase 3 trial results announced in March and the BLA filing in April. The accelerated pathway indicates a potential for earlier market entry for this new drug. The FDA has set a PDUFA date of November 30, 2026, for its decision.
At the time of this announcement, VRTX was trading at $446.13 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $113.6B. The 52-week trading range was $362.50 to $507.92. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.